Cartesian Therapeutics, Inc.
RNAC
Peringkat dalam Saham
#18421
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Harga Saham
$6.27
Terakhir disinkronkan: 2026-10-16
Kapitalisasi Pasar
$189.70M
Perubahan (1 hari)
-4.71%
Perubahan (1 tahun)
839.61%
Negara
US
Perdagangan Cartesian Therapeutics, Inc. (RNAC)
Kategori
Healthcare
Kapitalisasi pasar dari Cartesian Therapeutics, Inc.(RNAC)
Kapitalisasi Pasar: $189.70M
Per October 2026, Cartesian Therapeutics, Inc. memiliki kapitalisasi pasar sebesar $189.70M. Ini menjadikan Cartesian Therapeutics, Inc. sebagai perusahaan 18421st paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Cartesian Therapeutics, Inc. dari 2016 hingga 2026
RNAC dibandingkan dengan 5 teratas stocks paling populer
